The relationship between ketamine and Post-traumatic stress disorder is more specific than most coverage suggests, and the specificity is the useful part. The current position is that ketamine use for post-traumatic stress disorder is best described as emerging evidence, and its regulatory status is off-label. What follows sets out what the research actually shows, which populations it covers, how treatment is typically structured for this indication, what it costs, and where the genuine uncertainties sit. It does not attempt to sell the treatment, because the decision belongs to a person and their clinician rather than to a directory.
Applied to the United States, the point is this: someone who has not yet tried a first-line treatment is usually better served starting there, where the evidence is stronger, the cost lower and the risk profile better understood. Anyone comparing the United States programmes will find this decisive: the subanaesthetic dose used in this work is a fraction of the surgical dose, which is why the person stays awake, breathing independently and able to communicate. That holds in the United States as it does everywhere: the infusion can be slowed or stopped if someone becomes distressed, and knowing that in advance is itself a meaningful part of preparation. In the United States the same rule applies: a clinic willing to escalate frequency on request, or to supply product without meaningful assessment, has removed the safeguards that keep the risk manageable. Advertising routinely blurs the line between approved esketamine and off-label generic ketamine, and the distinction carries real consequences for coverage. It is the first thing to establish about any the United States programme.
What the research says about ketamine and Post-traumatic stress disorder
The trial evidence is real and also limited: studies tend to be small, follow-up periods short, and blinding is notoriously difficult when the dissociative effect is obvious to participants. Antagonism at the N-methyl-D-aspartate receptor appears to trigger a downstream cascade involving brain-derived neurotrophic factor and increased synaptic connectivity in mood-regulating regions. Coordination with an existing prescriber is a marker of considered practice, even though it slows the path to a first appointment.
There is a specific population for whom this conversation is most relevant, and it is narrower than the advertising implies. The trial evidence concentrates on adults with major depressive disorder who have not responded adequately to at least two antidepressant trials at appropriate doses and durations. If someone has never tried a first-line treatment, the reasonable clinical answer is usually to start there, because the evidence is stronger, the cost is lower and the risk profile is better understood. A clinic that agrees to treat anyone who asks, without reference to what has been tried, has replaced clinical judgement with a booking system.
It is worth pausing on the underlying medicine before returning to the United States. Integration is the term the field uses for the work of making sense of what happened, and it is the element most likely to be missing from a purely procedural clinic. The neuroplasticity hypothesis implies that the days following a session may be unusually receptive to therapeutic change, which suggests that pairing sessions with structured psychological support is not an upsell but a plausible way to use the window. Programmes vary enormously in how seriously they take this: some employ therapists and build integration sessions into the protocol, others hand over a worksheet, and some do nothing at all. Asking directly what integration support is included, and whether it costs extra, separates the two models quickly.
How a course is structured for this indication
Dosing for mood indications sits far below anaesthetic levels, typically calculated near 0.5 milligrams per kilogram of body weight and delivered slowly across about forty minutes. Patients researching the United States providers run into this constantly. Six infusions over roughly three weeks is the common induction pattern, though some programmes offer four and others extend to eight. The United States listings on this page are organised so that this is checkable rather than assumed. The trial protocols that produced the evidence base were run in monitored medical environments, and the monitoring was part of what made them safe rather than an accessory to it. Preparation before the first session matters for the same reason: people who know in advance what the dissociative period feels like generally find it far less alarming. It is worth carrying that into every conversation with a the United States provider.
Before comparing anything specific to the United States, the underlying clinical picture is worth stating properly. Screening is where a careful programme distinguishes itself, and it happens before anyone discusses scheduling. A thorough intake covers cardiovascular history, because of the blood pressure response; personal and family history of psychosis or bipolar disorder, because of the risk of precipitating an episode; hepatic function, because the liver metabolises the drug; substance use history; current medications and their interactions; and pregnancy status. It should also establish what has already been tried and at what dose, since the term treatment-resistant carries a specific meaning that only applies after adequate trials of at least two antidepressants. A consultation that skips most of this and moves quickly to a package price is telling you something about how the clinic is run.
Who is realistically a candidate for treatment of Post-traumatic stress disorder
The phrase treatment-resistant carries a specific meaning, and it only applies after documented trials at appropriate doses and durations. Screening should cover cardiovascular history, personal and family history of psychosis or bipolar disorder, hepatic function, substance use history and current medications. For anyone weighing options in the United States, esketamine, sold as Spravato, holds FDA approval for treatment-resistant depression in adults alongside an oral antidepressant, which puts it in a different regulatory category from generic infusions.
The setting is not incidental decoration. Trial protocols were run in monitored medical environments, and the structural elements of those environments are part of what makes the treatment defensible: a clinician credentialed to manage sedation present in the building, continuous monitoring of blood pressure, heart rate and oxygen saturation, resuscitation equipment available, and a defined plan for what happens if someone becomes acutely distressed. A comfortable recliner and dim lighting are pleasant. They are not a substitute for any of the preceding items, and a tour that emphasises the former while being vague about the latter has answered a question you did not ask.
Risks, side effects and screening
Read against the United States market, knowing in advance that the dissociative period is temporary, expected and monitored tends to make it considerably less frightening than encountering it unprepared. Legitimate programmes respond to the abuse potential with structure rather than reassurance: observed administration, no take-home injectable supply and defined session intervals. Nothing about the United States changes that. Monitoring during administration is not a formality, and the difference between continuous and intermittent observation is a reasonable thing to ask about directly.
The mechanism is where ketamine departs from the antidepressants most people have already tried. Conventional selective serotonin reuptake inhibitors work primarily on monoamine systems and typically need four to six weeks before any effect is assessable. Ketamine acts on the glutamate system, principally as an antagonist at the N-methyl-D-aspartate receptor, and the downstream cascade it appears to trigger involves a surge in brain-derived neurotrophic factor and a measurable increase in synaptic connections in regions associated with mood regulation. Researchers describe this as a window of heightened neuroplasticity. The clinically useful framing is that ketamine may open a period during which the brain is more amenable to change, which is precisely why the therapeutic work done around the infusion matters as much as the infusion.
What treatment costs and what insurance does
The headline per-session price usually excludes the consultation, any separately billed psychiatric evaluation, integration therapy and the maintenance sessions that follow. That is as true in the United States as anywhere else in the country. Because esketamine carries a Risk Evaluation and Mitigation Strategy, it can only be administered at certified centres with at least two hours of post-dose observation. Distance is a clinical variable in a treatment requiring six visits in three weeks, which is exactly why remote components deserve serious consideration rather than dismissal. Patients researching the United States providers run into this constantly.
Start with what is actually established
For anyone whose decision turns on cost, asking whether a provider offers esketamine as well as intravenous administration is among the higher-value questions available. Programmes differ enormously in how seriously they take the therapeutic work around the infusion, ranging from employed therapists to a photocopied worksheet. That is as true in the United States as anywhere else in the country. Any programme presenting six sessions as a complete and finished treatment, without discussing maintenance, has described half of what is involved. Nothing about the United States changes that. Commercial insurance seldom reimburses off-label intravenous administration, though the associated psychiatric evaluation is sometimes billable and worth asking about specifically.
It is worth pausing on the underlying medicine before returning to the United States. Esketamine, marketed as Spravato, occupies a different regulatory position that is routinely blurred in advertising. It is the S-enantiomer of ketamine, delivered as a nasal spray, and the FDA approved it in 2019 for treatment-resistant depression in adults used alongside an oral antidepressant, then in 2020 for depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour. Because it carries a Risk Evaluation and Mitigation Strategy, it can only be given at certified treatment centres, the patient must be observed for at least two hours afterwards, and they cannot drive until the following day. That is the entire practical difference for most people: esketamine is approved, insurable more often than not, and inconvenient; generic intravenous ketamine is off-label, usually paid out of pocket, and more flexible in how it is dosed.
Pairing sessions with structured psychological support follows directly from the mechanism, which makes its absence a substantive gap rather than a stylistic one. Comparing programmes in the United States is difficult because the variables that decide quality are rarely the ones displayed on a homepage. Read against the United States market, acting on a different receptor system explains both the speed of onset and why the treatment sometimes helps people whom other antidepressants have not. What happens financially if treatment is stopped partway through is a question best asked before the first session rather than after the third.
Making a decision about Post-traumatic stress disorder treatment
Applied to the United States, the point is this: continuous monitoring of blood pressure, heart rate and oxygen saturation is the baseline, because subanaesthetic dosing reliably produces a modest rise in the first two. The clinics that treat this as a psychiatric treatment rather than a procedure tend to build psychological support into the protocol rather than offering it as an upsell. Uncontrolled hypertension is treated as a serious caution for a straightforward physiological reason, and a programme that does not check blood pressure before dosing has skipped a step. Nausea is common enough that many programmes give an antiemetic pre-emptively rather than waiting to see. For anyone weighing options in the United States, randomised controlled trials have reported rapid reductions in depressive symptom scores after subanaesthetic infusions, often visible within hours to days rather than the weeks conventional antidepressants require.
None of this replaces a conversation with a clinician who knows your history. It is meant to make that conversation sharper, so that the appointment is spent on judgement rather than on establishing basic facts.
This page is general information, not medical advice, and no directory can assess whether a treatment is appropriate for an individual. Ketamine is a controlled substance with genuine risks, and its use for mood disorders is off-label apart from esketamine, which holds FDA approval for treatment-resistant depression under a restricted programme. Decisions about treatment should be made with a qualified clinician who knows your full history. If you are in crisis, contact the 988 Suicide and Crisis Lifeline by calling or texting 988 in the United States, or go to your nearest emergency department.